Scarna18: A Potential Drug Target and Tumor Biomarker (G677765)

Target Name: SCARNA18

NCBI ID: G677765

SCARNA18

Other Name(s): SCARNA18A | U109 | Small Cajal body-specific RNA 18 | small Cajal body-specific RNA 18

Scarna18: A Potential Drug Target and Tumor Biomarker

SCARNA18 (SCARNA18A) is a protein that is expressed in various tissues of the body, including the brain, nervous system, and endothelial cells. Its name is derived from its human gene sequence SCARNA18. There is currently no exact biological function, but there are potential as drug targets or biomarkers.

SCARRNA18A is a long non-coding RNA (lncRNA) whose coding region consists of approximately 1800 nucleotides. It has slightly different expression patterns in different species but is highly expressed in humans. Research shows that SCARRNA18A plays an important role in a variety of neurological diseases, such as neurodegenerative diseases, mental disorders and neurodevelopmental disorders.

In addition, SCARRNA18A is also closely related to the occurrence and development of various tumors. Studies have shown that the expression level of SCARNA18A is closely related to the prognosis and treatment response of various cancers, such as lung cancer, liver cancer, breast cancer, etc. Therefore, SCARRNA18A is considered a potential tumor biomarker that can be used for tumor diagnosis and treatment.

In addition to serving as a drug target or biomarker, SCARRNA18A also has other biological functions. For example, studies have shown that SCARRNA18A can regulate neuronal apoptosis and participate in neuronal survival and synaptic plasticity. In addition, SCARRNA18A is also involved in biological processes such as cell signaling and cell proliferation.

As an emerging biomarker, SCARRNA18A has broad application prospects in drug development and tumor research. Through in-depth study of the function and mechanism of SCARRNA18A, it is expected to provide new ideas and methods for the treatment of neurological diseases and tumors.

Protein Name: Small Cajal Body-specific RNA 18

The "SCARNA18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets